Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | FPR2 | P25090 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7419479 | 0.84 | NPSR1 (0.45) | ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL7419476 | 0.84 | NPSR1 (0.45) | ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL8014043 | 0.83 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1KMT2AFPR2MEN1 | |
| SCHEMBL15756642 | 0.83 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1KMT2AFPR2MEN1 | |
| SCHEMBL8014033 | 0.83 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1KMT2AFPR2MEN1 | |
| SCHEMBL2574455 | 0.82 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1KMT2AFPR2MEN1 | |
| SCHEMBL19926836 | 0.82 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1KMT2AFPR2MEN1 | |
| SCHEMBL19926834 | 0.82 | ALDH1A1 (0.58) | ALDH1A1L3MBTL1KMT2AFPR2MEN1 | |
| SCHEMBL21261499 | 0.82 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1KMT2AFPR2MEN1 | |
| SCHEMBL12205311 | 0.82 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1KMT2AFPR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118217402-A | Combination therapy for C3 inhibition | 阿佩利斯制药有限公司 | 2024-06-21 | — | — | CN | claimed |
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | claimed |
| EP-4105224-A1 | LONG-ACTING COMPSTATIN ANALOGS AND USES THEREOF | Apellis Pharmaceuticals, Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | claimed |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12528836-B2 | Dosing regimens | APELLIS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12458695-B2 | Dosing regimens and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-3524258-B1 | METHODS OF TREATING CHRONIC DISORDERS WITH COMPLEMENT INHIBITORS | APELLIS PHARMACEUTICALS INC (US) | 2025-10-01 | — | — | EP | disclosed |
| US-20250282823-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4585228-A2 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | Apellis Pharmaceuticals, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250170209-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250170210-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | APELLIS PHARMACEUTICALS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-11338013-B2 | Combination therapy for C3 inhibition | APELLIS PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3996744-A1 | VIRAL VECTOR THERAPY | Apellis Pharmaceuticals, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-105582523-B | Compstatin and analogs thereof for ocular disorders | 阿佩利斯制药公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-2707384-B1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11291407-B2 | Detection of high risk drusen | APELLIS PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11292815-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | APELLIS PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| WO-2022061304-A1 | METHODS OF TREATING EYE DISORDERS | APELLIS PHARMACEUTICALS, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291407-B2 | Detection of high risk drusen | EXOSC4, EXOSC5, EXOSC10 | ALDH1A1 998/4885L3MBTL1 1592/4885KMT2A 2702/4885 |
| US-20250170209-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | ALDH1A1 4748/4885L3MBTL1 1850/4885KMT2A 4187/4885 |
| US-12458695-B2 | Dosing regimens and related compositions and methods | C1QBP, C3AR1, C9 | ALDH1A1 4748/4885L3MBTL1 1850/4885KMT2A 4187/4885 |
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | C9, C3AR1, SERPINC1 | ALDH1A1 4858/4885L3MBTL1 1187/4885KMT2A 4671/4885 |
| US-20250170210-A1 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | C1QBP, C3AR1, C9 | ALDH1A1 4748/4885L3MBTL1 1850/4885KMT2A 4187/4885 |
| US-20250282823-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | C3AR1, C9, C1QBP | ALDH1A1 4771/4885L3MBTL1 1962/4885KMT2A 4114/4885 |
| US-12528836-B2 | Dosing regimens | CFD, CFB, VIP | ALDH1A1 4785/4885L3MBTL1 1912/4885KMT2A 4279/4885 |
| US-11292815-B2 | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods | ANPEP, ADAM8, MSTN | ALDH1A1 4812/4885L3MBTL1 1239/4885KMT2A 2367/4885 |
| US-11338013-B2 | Combination therapy for C3 inhibition | C3AR1, C5, CFH | ALDH1A1 4537/4885L3MBTL1 782/4885KMT2A 3072/4885 |
| US-20260062448-A1 | CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND USES THEREOF | MASP2, CLEC4M, C1QBP | ALDH1A1 4798/4885L3MBTL1 1008/4885KMT2A 3962/4885 |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | C9, C3AR1, SERPINC1 | ALDH1A1 4856/4885L3MBTL1 1189/4885KMT2A 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.